BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38893073)

  • 1. Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study.
    Vrancken Peeters NJMC; van Til JA; Huberts AS; Siesling S; Husson O; Koppert LB
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
    Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
    JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
    Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
    Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsiveness and minimal clinically important difference of the EQ-5D-5L in cervical intraepithelial neoplasia: a longitudinal study.
    Hu X; Jing M; Zhang M; Yang P; Yan X
    Health Qual Life Outcomes; 2020 Oct; 18(1):324. PubMed ID: 33008423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma.
    Huang D; Zeng D; Tang Y; Jiang L; Yang Q
    Qual Life Res; 2024 Feb; 33(2):491-505. PubMed ID: 37938402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
    Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
    J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
    [No Abstract]   [Full Text] [Related]  

  • 9. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
    Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.
    Xu RH; Wong ELY; Jin J; Dou Y; Dong D
    Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
    Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
    Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
    Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
    Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who Benefits From Hip Arthroplasty or Knee Arthroplasty? Preoperative Patient-reported Outcome Thresholds Predict Meaningful Improvement.
    Langenberger B; Steinbeck V; Busse R
    Clin Orthop Relat Res; 2024 May; 482(5):867-881. PubMed ID: 38393816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
    Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
    J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.